EL - EssilorLuxottica Société anonyme
PAR
->
Healthcare
->
Medical Instruments & Supplies
Paris,
France
Type: Equity
EL price evolution
EL
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $1977 | $1727 | $1854 | $1752 |
| Inventory | $2255 | $2175 | $2307 | $2603 |
| Total current assets | $7215 | $7922 | $8534 | $8915 |
| Long term investments | ||||
| Property, plant & equipment | $5206 | $4969 | $4969 | $5039 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $21317 | $21677 | $22700 | $23283 |
| Current liabilities | ||||
| Accounts payable | $1135 | $1440 | $1197 | $1252 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5486 | $5702 | $5416 | $6574 |
| Long term debt | $7311 | $7267 | $7265 | $6640 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $16233 | $16363 | $16956 | $17571 |
| Shareholders' equity | ||||
| Retained earnings | $13031 | $13427 | $13950 | $13858 |
| Other shareholder equity | -$1057 | -$1140 | -$1014 | -$856 |
| Total shareholder equity | ||||
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 29 Jul 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4958 | |||
| Short term investments | ||||
| Net receivables | $1727 | $1452 | $1629 | $1702 |
| Inventory | $2175 | $2979 | $2920 | $2505 |
| Total current assets | $7922 | $9139 | $9298 | $9768 |
| Long term investments | ||||
| Property, plant & equipment | $4969 | $4976 | $4599 | $2280 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12203 | |||
| Total investments | ||||
| Total assets | $21677 | $23415 | $20910 | $21971 |
| Current liabilities | ||||
| Accounts payable | $1440 | $1670 | $1822 | $1692 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5702 | $6240 | $5815 | $5298 |
| Long term debt | $7267 | $7117 | $5144 | $5537 |
| Total noncurrent liabilities | $10582 | |||
| Total debt | ||||
| Total liabilities | $16363 | $17830 | $15320 | $15880 |
| Shareholders' equity | ||||
| Retained earnings | $13427 | $13991 | $13912 | $12244 |
| Other shareholder equity | -$1140 | $5585 | -$762 | -$436 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3361 | $3871 | $3940 | $4280 |
| Cost of revenue | ||||
| Gross Profit | $2433 | $2779 | $2833 | $3126 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $2298 | $2444 | $2284 | $2544 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$24 | $7 | $151 | $195 |
| Interest expense | -$57 | -$50 | -$49 | -$58 |
| Net income | ||||
| Net income | -$156 | -$284 | $330 | $313 |
| Income (for common shares) | ||||
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 29 Jul 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15609 | $15910 | $17737 | $16215 |
| Cost of revenue | ||||
| Gross Profit | $11186 | $11346 | $13432 | $12381 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $9621 | $9575 | $9888 | $9763 |
| Operating income | $2618 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $363 | $387 | $628 | $456 |
| Interest expense | -$211 | -$124 | -$136 | $173 |
| Net income | ||||
| Net income | $390 | $1006 | $2390 | $2870 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$160 | -$960 | -$735 | -$557 |
| Financing activities | ||||
| Dividends paid | -$240 | -$947 | -$710 | -$474 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$226 | -$2035 | -$1059 | -$489 |
| Effect of exchange rate | $11 | $1 | -$5 | $19 |
| Change in cash and equivalents | -$1045 | -$634 | -$328 | -$90 |
| (in millions $) | 30 Jul 2024 | 30 Jul 2023 | 30 Jul 2022 | 29 Jul 2021 |
|---|---|---|---|---|
| Net income | $2875 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $3631 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$960 | -$3217 | -$945 | -$1864 |
| Financing activities | ||||
| Dividends paid | -$947 | -$925 | -$840 | -$753 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$2035 | $1590 | -$3036 | -$1892 |
| Effect of exchange rate | $1 | -$32 | -$60 | $61 |
| Change in cash and equivalents | -$634 | $72 | -$1001 | -$64 |
News
Fundamentals
| Market cap | $97.28B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 358.98M |
| Revenue | $15.45B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $203.00M |
| Revenue Q/Q | -4.46% |
| Revenue Y/Y | -0.33% |
| P/E ratio | 479.23 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 6.30 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $0.57 |
|---|---|
| ROA | 0.91% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.32 |
| Quick ratio | 0.90 |